Stem Cell Therapeutics Corp.

Stem Cell Therapeutics Corp.

July 09, 2009 13:23 ET

Stem Cell Therapeutics Announces Issuance of Patents in India

These patents cover combined regulation of neural stem cell production, and a composition for increasing neural stem cell number or for producing specialized neural stem cell progeny.

CALGARY, ALBERTA--(Marketwire - July 9, 2009) - Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or "the Company") has been issued two patents in India: Indian Patent No. 229684 entitled, "Combined Regulation of Neural Cell Production" and Indian Patent No. 229924 entitled, "A Composition for Increasing Neural Stem Cell Number and In Vitro Method of Using the Same". Together, these patents cover pharmaceutical compositions for increasing neural stem cell number or for producing specialized neural stem cell progeny, with the compositions comprising prolactin in combination with other neural stem cell proliferating agents or differentiating agents, such as erythropoietin ("EPO"). Methods for using prolactin and other such agents in neural stem cell culture are also covered, with the resulting cells being useful, for example, in regenerative transplant therapy.

Dr. Alan Moore, President and CEO, commented as follows:

"Overall, India is playing a valuable role in our development programs. It is therefore increasingly important to address intellectual property issues in India. These two patents are part of that process."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury and multiple sclerosis.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information